Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-15 5:05 pm Unchanged |
2025-02-21 | 13G | Singular Genomics Systems, Inc. OMIC |
ARCH Venture Fund IX, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2025-05-15 5:04 pm Unchanged |
2025-03-31 | 13G | Beam Therapeutics Inc. BEAM |
ARCH Venture Fund IX, L.P. | 4,600,747 4.600% |
0 (Unchanged) |
Filing History |
| 2025-02-14 4:55 pm Purchase |
2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
ARCH Venture Fund IX, L.P. | 1,829,886 13.100% |
6,000 (+0.33%) |
Filing History |
| 2025-02-14 4:55 pm Sale |
2024-12-31 | 13G | Beam Therapeutics Inc. BEAM |
ARCH Venture Fund IX, L.P. | 4,600,747 5.600% |
-902,907 (-16.41%) |
Filing History |
| 2024-11-14 5:12 pm Purchase |
2024-09-30 | 13G | Sana Biotechnology, Inc. SANA |
ARCH Venture Fund IX, L.P. | 46,028,125 20.600% |
1,883,181 (+4.27%) |
Filing History |
| 2024-10-29 6:32 pm Purchase |
2024-04-02 | 13D | Boundless Bio, Inc. BOLD |
ARCH Venture Fund IX, L.P. | 2,699,970 12.100% |
2,699,970 (New Position) |
Filing History |
| 2024-02-14 3:18 pm Purchase |
2023-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
ARCH Venture Fund IX, L.P. | 1,823,886 14.500% |
3,250 (+0.18%) |
Filing History |
| 2024-02-14 3:18 pm Sale |
2023-12-31 | 13G | Beam Therapeutics Inc. BEAM |
ARCH Venture Fund IX, L.P. | 5,503,654 6.800% |
-367,496 (-6.26%) |
Filing History |
| 2024-02-09 5:35 pm Purchase |
2023-12-31 | 13G | Sana Biotechnology, Inc. SANA |
ARCH Venture Fund IX, L.P. | 44,144,944 22.400% |
65,536 (+0.15%) |
Filing History |
| 2024-02-09 5:35 pm Sale |
2023-07-24 | 13G | Gossamer Bio, Inc. GOSS |
ARCH Venture Fund IX, L.P. | 0 0.000% |
-8,055,916 (Position Closed) |
Filing History |
| 2023-02-13 4:07 pm Purchase |
2022-12-31 | 13G | Sana Biotechnology, Inc. SANA |
ARCH Venture Fund IX, L.P. | 44,079,408 23.100% |
817 (+0.00%) |
Filing History |
| 2022-09-20 4:58 pm Sale |
2022-08-12 | 13D | Karuna Therapeutics, Inc. KRTX |
ARCH Venture Fund IX, L.P. | 0 0.000% |
-2,946,891 (Position Closed) |
Filing History |
| 2022-09-13 3:45 pm Sale |
2022-08-12 | 13D | Vir Biotechnology, Inc. VIR |
ARCH Venture Fund IX, L.P. | 13,552,310 10.200% |
-5,636,784 (-29.37%) |
Filing History |
| 2022-05-10 5:05 pm Purchase |
2021-12-20 | 13D | Vir Biotechnology, Inc. VIR |
ARCH Venture Fund IX, L.P. | 19,189,094 14.700% |
3,374 (+0.02%) |
Filing History |
| 2022-02-14 12:04 pm Sale |
2021-12-31 | 13G | Beam Therapeutics Inc. BEAM |
ARCH Venture Fund IX, L.P. | 5,871,150 8.600% |
-2,371,889 (-28.77%) |
Filing History |
| 2022-02-14 12:04 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
ARCH Venture Fund IX, L.P. | 1,820,636 15.100% |
1,820,636 (New Position) |
Filing History |
| 2022-02-10 5:12 pm Purchase |
2021-12-31 | 13G | Sana Biotechnology, Inc. SANA |
ARCH Venture Fund IX, L.P. | 44,078,591 23.300% |
44,078,591 (New Position) |
Filing History |
| 2022-02-04 2:13 pm Purchase |
2021-12-31 | 13G | Singular Genomics Systems, Inc. OMIC |
ARCH Venture Fund IX, L.P. | 126,711 5.300% |
126,711 (New Position) |
Filing History |
| 2022-01-10 5:02 pm Sale |
2021-12-20 | 13D | Vir Biotechnology, Inc. VIR |
ARCH Venture Fund IX, L.P. | 19,185,720 14.700% |
-2,589,653 (-11.89%) |
Filing History |
| 2021-07-12 5:02 pm Sale |
2021-06-22 | 13D | Vir Biotechnology, Inc. VIR |
ARCH Venture Fund IX, L.P. | 21,775,373 16.700% |
-4,915,244 (-18.42%) |
Filing History |